Long non‐coding RNAs in rheumatoid arthritis

Rheumatoid arthritis, a disabling autoimmune disease, is associated with altered gene expression in circulating immune cells and synovial tissues. Accumulating evidence has suggested that long non‐coding RNAs (lncRNAs), which modulate gene expression through multiple mechanisms, are important molecu...

Full description

Saved in:
Bibliographic Details
Published in:Cell proliferation Vol. 51; no. 1
Main Authors: Li, Zheng, Li, Xingye, Jiang, Chao, Qian, Wenwei, Tse, Gary, Chan, Matthew T.V., Wu, William K.K.
Format: Journal Article
Language:English
Published: England John Wiley and Sons Inc 01.02.2018
Subjects:
Animals
Arthritis, Rheumatoid - genetics
Arthritis, Rheumatoid - immunology
Biomarkers - metabolism
Gene Expression - genetics
Gene Expression Regulation - genetics
Humans
Review
RNA, Long Noncoding - genetics
T-Lymphocytes - immunology
ISSN:0960-7722, 1365-2184, 1365-2184
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis, a disabling autoimmune disease, is associated with altered gene expression in circulating immune cells and synovial tissues. Accumulating evidence has suggested that long non‐coding RNAs (lncRNAs), which modulate gene expression through multiple mechanisms, are important molecules involved in immune and inflammatory pathways. Importantly, many studies have reported that lncRNAs can be utilized as biomarkers for disease diagnosis and prognostication. Recently, dysregulation of lncRNAs in rheumatoid arthritis and other autoimmune diseases has been revealed. Experimental studies also confirmed their crosstalk with matrix metalloproteinases, nuclear factor‐κB signalling and T‐cell response pertinent to autoimmunity and inflammation. Circulating lncRNAs, such as HOTAIR, differentiated patients with rheumatoid arthritis from healthy subjects. Taken together, lncRNAs are good candidates as biomarkers and therapeutic targets in rheumatoid arthritis. Further investigation on in vivo delivery of these regulatory molecules and large‐cohort validation of their clinical applicability may be useful.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0960-7722
1365-2184
1365-2184
DOI:10.1111/cpr.12404